Knockin marmoset reporters for non-invasive measuring of genome-editing efficiency

Knockin狨猴报告基因组编辑效率的非侵入性测量

• 批准号: 10450134
• 负责人: Guoping Feng
• 金额: $ 79.5万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10450134
• 关键词: Adenine; Animal Model; Animal Testing; Animals; Basic Science; Bioluminescence; Birth; Breeding; Callithrix; Callithrix jacchus jacchus; Cells; Cercopithecidae; Clinical; Clustered Regularly Interspaced Short Palindromic Repeats; Codon Nucleotides; DNA; Dependovirus; Development; Directed Molecular Evolution; Disadvantaged; Electrons; Engineering; Enhancers; Family; Fluorescence; Fluorescence-Activated Cell Sorting; Genes; Genetic Engineering; Genetic Models; Housing; Human; Intervention; Knock-in; Luciferases; Macaca; Measures; Mediating; Modeling; Monitor; Mutate; Peptides; Preclinical Testing; Pregnancy; Primates; Protein Engineering; Reporter; Reproduction; Resolution; Rodent Model; Sequence Deletion; Sexual Maturation; Sorting - Cell Movement; Specificity; System; Technology; Terminator Codon; Testing; Tissues; United States Food and Drug Administration; Variant; Venus; base; base editing; base editor; bioluminescence imaging; charge coupled device camera; cost; efficacy testing; gene therapy; genome editing; human disease; new technology; nonhuman primate; novel therapeutic intervention; repaired; screening; single cell analysis; single cell sequencing; targeted nucleases; whole body imaging

Project Summary The past decade has seen unprecedented advances in genome editing technologies and the approval of several targeted gene therapies by the Food & Drug Administration. As such, targeted endonuclease-based approaches to gene therapy now hold realistic promise for the widespread treatment and reversal of a large number of human diseases. Although early versions of CRISPR/Cas systems suffered from problems with efficiency and specificity, recent advances achieved through directed-evolution, targeted protein engineering, and the identification of editing enhancers have put widespread use of gene therapy within reach. However, one major hurdle between the basic science and the implementation of safe and effective clinical interventions is a lack of suitable large animal models for pre-clinical testing of new technologies and therapeutic strategies. Here, we propose a strategy to generate two reporter lines in the common marmoset (Callithrix jacchus) that will be used for monitoring of both on- and off-target editing by Cas9 and adenine base editors at single-cell resolution. Large animal reporters must be highly efficient and capable of testing multiple aspects of gene editing if they are to be broadly useful and capable of overcoming the slow sexual maturation and gestational periods of primates. Taking this into consideration, we will utilize well-established fluorescent reporters in conjunction with a newly-developed variant of luciferase called Akaluc that can be used for non-invasive bioluminescent imaging in marmosets with single-cell sensitivity. We will generate an initial set of two marmoset reporters capable of testing knock-in and adenine base editing in a non-invasive manner through on-target editing-mediated activation of Venus-Akaluc expression. Following initial screening for on-target editing via whole-body imaging with an electron-multiplying charge-couple device (EMCCD) camera, tissue can be collected from these reporter animals and used for single-cell analyses of both on- and off-target editing through fluorescence activated cell sorting (FACS) and single-cell sequencing. Our approach establishes a versatile and efficient platform for testing editing technologies in a non-human primate species and can be easily and rapidly adapted to evolving technologies, making it a valuable system for accelerating the development of safe and effective gene therapies.

项目摘要 过去十年，基因组编辑技术取得了前所未有的进步， 美国食品和药物管理局的几种靶向基因疗法。因此，基于靶向核酸内切酶的 基因治疗的方法现在为广泛的治疗和逆转大规模的癌症提供了现实的希望。 人类疾病的数量。尽管CRISPR/Cas系统的早期版本存在以下问题： 效率和特异性，通过定向进化，靶向蛋白质工程， 以及编辑增强子的鉴定已经使基因治疗的广泛使用触手可及。然而，在这方面， 基础科学和安全有效的临床干预措施的实施之间的一个主要障碍 缺乏合适的大型动物模型用于新技术和治疗策略的临床前测试。 在这里，我们提出了一种策略，在普通绒猴（Callithrix jacchus）中产生两个报告细胞系， 将用于监测在单细胞中Cas9和腺嘌呤碱基编辑器的靶上和脱靶编辑。 分辨率大型动物报告基因必须是高效的，并且能够测试基因的多个方面。 编辑，如果他们是广泛有用的，并能够克服缓慢的性成熟和妊娠 灵长类的时期。考虑到这一点，我们将利用成熟的荧光报告基因来 与新开发的称为Akaluc的荧光素酶变体结合，可用于非侵入性 生物发光成像在绒猴与单细胞的敏感性。我们将生成一组初始的两个 绒猴报告子，其能够通过以下方式以非侵入性方式测试敲入和腺嘌呤碱基编辑： 中靶编辑介导的Venus-Akaluc表达的激活。初始筛选后， 通过电子倍增电荷耦合器件（EMCCD）相机的全身成像进行编辑，组织可以 从这些报告动物中收集并用于对靶编辑和脱靶编辑的单细胞分析 通过荧光激活细胞分选（FACS）和单细胞测序。我们的方法建立了一个 用于在非人类灵长类物种中测试编辑技术的通用且高效的平台，并且可以 轻松快速地适应不断发展的技术，使其成为加速 开发安全有效的基因疗法。